Article
Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.
Pediatric blood & cancer - 1 Jan 2015
Smith Malcolm A, Hampton Oliver A, Reynolds C Patrick, Kang Min H, Maris John M, Gorlick Richard, Kolb E Anders, Lock Richard, Carol Hernan, Keir Stephen T, Wu Jianrong, Kurmasheva Raushan T, Wheeler David A, Houghton Peter J
Abstract excerpt
BACKGROUND: BMN 673 is a potent inhibitor of poly-ADP ribose polymerase (PARP) that is in clinical testing with a primary focus on BRCA-mutated cancers. BMN 673 is active both through inhibiting PARP catalytic activity and by tightly trapping PARP to DNA at sites of single strand breaks. PROCEDURE: BMN 673 was tested in vitro at concentrations ranging from 0.1 nM to 1 μM and in vivo at a daily dose of 0.33 mg/kg...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.